

## Research Article



## Effect of Hypoxia on *In Vitro* Adhesion, Biofilm Formation and Antifungal Susceptibility of *Candida albicans*

Payal Gupta<sup>1</sup>, Ramesh C. Meena<sup>2</sup>, Nishant Rai<sup>1</sup>, Navin Kumar<sup>1\*</sup>

<sup>1</sup>Department of Biotechnology, Graphic Era University, 566/6, Bell Road, Clement Town, Dehradun, Uttarakhand, India.

<sup>2</sup>Department of Molecular Biology, Defense Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi, India.

\*Corresponding author's E-mail: [navinbajpai@gmail.com](mailto:navinbajpai@gmail.com)

Accepted on: 03-04-2015; Finalized on: 30-04-2015.

### ABSTRACT

*Candida albicans* is a well known pathogen in nosocomial infections. Adhesion, biofilm and resistance to antifungal are main virulence properties. Pathogen faces hypoxic microenvironment in tissues which affects pathogenesis. We set our experiments to investigate directly the effect of hypoxia on growth, *in vitro* adhesion, biofilm formation and antifungal susceptibility of pathogen. Effect of hypoxia on growth was checked by spotting assays. *In vitro* adhesion, biofilm development and susceptibility of biofilm to amphotericin B were performed on polystyrene plates and quantified by XTT assay in RPMI 1640 and YNB media. Experiments were performed in triplicates and Student's t-test was used for statistical analysis. Cells grew well under hypoxia. Adhesion was reduced upon exposure to hypoxia in YNB medium but remains unchanged in RPMI-1640. Hypoxia increased biofilm activity to  $287.24 \pm 22.05\%$  in RPMI 1640 and  $130.02 \pm 2.99\%$  in YNB. Biofilm susceptibility to amphotericin B was reduced significantly under hypoxia in RPMI. In conclusion, hypoxia increased biofilm formation and reduced susceptibility to amphotericin B of *C. albicans* in RPMI 1640.

**Keywords:** Hypoxia, *Candida albicans*, biofilm, adhesion, XTT, RPMI-1640

### INTRODUCTION

*Candida albicans* is the most common opportunistic fungal pathogen responsible for candidiasis, a life threatening infections ranging from superficial to systemic, particularly in the patients with compromised immunity<sup>1,2</sup>. Candidiasis stands fourth among the nosocomial ailments, causing a mortality rate ranging 15% to 35%<sup>3</sup>. Antibiotic resistance of *C. albicans* is marked in the recent report of year 2013 from Center for Disease Control and Prevention, U. S. Department of Health and Human Services<sup>4</sup>.

Yeast to hyphal transition, secretion of hydrolytic enzymes, adherence to host tissue and biofilm formation are the major virulence factors of *C. albicans*<sup>5,6</sup>. Biofilm formation is a one of the major factors that determines drug resistance by *C. albicans*<sup>7,8</sup>. Tissue hypoxia, a state of low oxygen microenvironment (2.5-9 % in normal tissues and approximately 1% in damaged tissues) of host tissue is an important factor which regulates biofilm formation by pathogen<sup>9,10</sup>. Few studies has demonstrated that anaerobic conditions modulate biofilm differently in different strains and isolates; but in most of the studies anaerobic conditions do not support the growth of the biofilm<sup>11,12</sup>. Hypoxia mediated transcriptional response has been investigated well in *C. albicans* and other fungi<sup>13-15</sup>. Hypoxia upregulated the genes of biosynthesis of sterol, lipids, heme along with glycolytic pathways. Sterol regulatory element-binding proteins (SREBPs) regulate hypoxic responses in mammals<sup>16</sup>. But in *C. albicans*, the role of SREBPs is replaced by different regulator Upc2 and Ecm22 which binds sterol regulatory element in the promoters of target genes<sup>17</sup>. In *C. albicans*, Upc2 and Efg1 (transcription factors) regulate genes of

ergosterol and fatty acid biosynthesis pathways respectively under hypoxic conditions while Tye7 and Gal4 induce genes of glycolytic pathway in hypoxia<sup>1,18,19</sup>. In *C. parapsilosis*, similar kind of transcriptional responses were reported during biofilm formation and hypoxia, suggesting the interrelationship of biofilm development with hypoxia<sup>20</sup>. In a similar study on *C. glabrata*, hypoxia is reported to enhance the biofilm formation *in vitro*, approximately by 2.5 times<sup>21</sup>.

To the best of our knowledge, there is no direct study indicating the role of hypoxia in the virulence of *C. albicans*. Therefore, in this study, we planned to study the direct effect of hypoxia (1% Oxygen) upon key virulence factors like growth, *in vitro* adhesion, biofilm formation and susceptibility to drug in two growth media, RPMI and YNB.

### MATERIALS AND METHODS

#### Cultures, Culture condition and Chemicals

*C. albicans* (SC5314) strain was provided by K. Ganeshan from Imtech Chandigarh, Punjab, India. Strain was routinely cultivated at 37°C in YPD medium (1% yeast extract, 2% Bacto-peptone and 2% dextrose; BD) in orbital shaker at 120 rpm. Biofilm and adhesion assays were performed in RPMI 1640 (HiMedia) medium supplemented with 50 mM HEPES and L-Glutamine, pH 7.0 (referred as to RPMI 1640 henceforth) and YNB medium (0.67% yeast nitrogen base w/o amino acids with ammonium sulfate supplemented with 2% dextrose; BD; pH 7.0) on the surface of pre-sterilized, polystyrene, flat bottomed 96-well microtiter plates (HiMedia)<sup>22,23</sup>. All other routine chemicals of molecular grade were procured from Merck and plastic-wares from Tarson.



Amphotericin B (amp B), Menadione and 2,3-bis (2-methoxy-4-nitro-sulphophenyl)-2H-tetrazolium-5-carboxanilide (XTT) were purchased from HiMedia. For exposure to hypoxic conditions, plates were incubated in a hypoxic chamber (Multi-gas incubator, CO<sub>2</sub>/O<sub>2</sub> incubator Model GA156, LEEC, UK) with 1% O<sub>2</sub>, 5% CO<sub>2</sub> and 94% N<sub>2</sub>. Normoxic exposures were given by incubating the plates in normal incubator shaker and the data is considered as control.

### Effect of Hypoxia on Growth

Growth of cells under hypoxia and normoxia was analyzed by plate spotting assay<sup>24</sup>. Log phase cells of *C. albicans* (OD<sub>600nm</sub>: 0.6) were spotted in 10 fold serial dilutions (10<sup>3</sup>, 10<sup>2</sup>, 10<sup>1</sup>, 10<sup>0</sup> cells) onto YPD and YNB agar plates. For normoxic plates were incubated at 37°C for 18 hours (h) while for hypoxia, plates were incubated in hypoxia chamber at 37°C for 18 h. Experiments were done in triplicates.

### Effect on Adhesion

The *in vitro* effect of hypoxia on adherence of *C. albicans* was studied on polystyrene surface using flat bottomed 96-well microtiter plate in YNB and RPMI-1640 medium<sup>21</sup>. 100 µl of cell suspension (10<sup>7</sup> cells/ml) in both medium was added to the wells and plates were incubated at 37°C for 90 minutes (min) with shaking on normoxic and hypoxic conditions, separate plates were used. After incubation, unadhered cells were removed by washing wells twice with 200 µl of PBS.

The adhered cells were quantified in each well using XTT-reduction assay. Absorbance was measured at 450 nm using ELISA Reader (Molecular Devices, SPECTRA max M2). Values are represented in terms of relative metabolic activity (RMA) in percentage, relative to the adhesion of respective normoxia control (Mean of metabolic activities of normoxia control is taken as 100%).

### Effect on Biofilm Formation

*C. albicans in vitro* biofilm was developed on the surface of pre-sterilized, polystyrene, 96-well microtiter plate<sup>25</sup>. Briefly, 100 µl of cell suspension, prepared in PBS at a concentration of 10<sup>7</sup> cells/ml was added to each well. Plates were incubated for 90 min at 37°C on normoxic condition for adhesion phase. After incubation, wells were washed twice with 200 µl of PBS and 200 µl of culture media was added to the wells and plates were incubated at 37°C on normoxia and hypoxia for 60 h with shaking. Afterwards, wells were again washed twice with 200 µl of PBS and biofilm developed was quantified by XTT reduction assay<sup>7</sup> at 450 nm using ELISA Reader (Molecular Devices, SPECTRA max M2).

Biofilm developed is represented in terms of relative metabolic activity (RMA) in percentage, relative to the biofilm of respective normoxia control (Mean of metabolic activities of normoxia control is taken as 100%).

### Effect on Biofilm Antifungal Drug Susceptibility

Effect of hypoxia upon susceptibility of biofilm development to antifungal drug was analyzed in the presence of different concentrations of amphotericin B (0, 0.0625, 0.125, 0.25 µg/ml) following the methodology as mentioned above by XTT reduction assay<sup>7,21</sup>. We investigated the susceptibility of *C. albicans* biofilm development to amphotericin B in both the media, YNB and RPMI 1640 upon exposure to hypoxia in comparison to normoxia controls.


### Statistical Analysis

All experiments were performed in triplicates and values presented are the mean with standard deviation, obtained from three different observations for XTT assays. Student's t-test was used for statistical analysis and a value of  $p < 0.05$  was considered statistically significant (\*) and  $p < 0.001$  as highly significant (\*\*) for comparisons<sup>16</sup>.

## RESULTS

### Hypoxia did not affect the growth of *C. albicans*

For determining the effect of hypoxia on growth of *C. albicans*, we performed growth assay where the cell containing plates were incubated under hypoxic and normoxic conditions. Cells grew well under both the conditions (Figure 1).



**Figure 1:** Growth and cell viability of *C. albicans* in spotting assays onto YPD agar plates upon exposure to normoxia and hypoxia.

### *C. albicans* Adhesion was not increased under Hypoxia

*In vitro* adherence of *C. albicans* cells, under hypoxia and normoxia was investigated in 96-well flat bottom polystyrene plates.

Under hypoxic condition, the adhesion potential of the cells was found to be reduced significantly in YNB medium (RMA: 73.24 ± 4.4756%;  $P < 0.05$ ) while remain unchanged in RPMI-1640 (101.35 ± 2.645%;  $P > 0.05$ ) compared to that of normoxia control (Figure 2A).

### Hypoxia increased Biofilm formation by *C. albicans*

The biofilm was formed in polystyrene plates in both media under both the conditions. The biofilm formation, under hypoxia was strikingly increased in RPMI-1640 (RMA: 287.24 ± 8.26%;  $P < 0.001$ ), while in YNB, hypoxia increased it significantly as compared to control (RMA: 130.02 ± 1.2%;  $P < 0.05$ ) (Figure 2B).





Figure 2

**Figure 2:** *In vitro* adhesion and biofilm formation by *C. albicans*. **A:** Relative metabolic activities (%) of adhesion of *C. albicans* cells under different conditions in different media. **B:** Relative metabolic activities (%) of biofilm formation by *C. albicans* cells under different conditions in different media. Mean values of RMA  $\pm$  SD of three independent experiments are shown;  $P < 0.05$  is considered statistically significant and  $P < 0.001$  highly significant and represented as (\*) and (\*\*) respectively.

### Hypoxia reduced Biofilm Antifungal Susceptibility of *C. albicans*

Biofilm was developed in the presence of different concentrations of amphotericin B (as shown in Figure 3) in polystyrene 96-well plate. In RPMI media, in the presence of different concentrations of amphotericin B, biofilm activities were found significantly higher under hypoxic conditions than that of normoxic controls. While in YNB, in the presence of different concentrations of drug, biofilm activities under hypoxia were not found higher to that normoxia (Figure 3A, 3B).



**Figure 3:** *In vitro* biofilm susceptibility to amphotericin B by *C. albicans*. **A:** Susceptibility of biofilm development in YNB medium. **B:** Susceptibility of biofilm development in RPMI-1640 medium. Results were shown here as mean  $\pm$  SD of A450 plotted on Y-axis against concentration of amphotericin B on X-axis. Statistically significant differences in biofilm activities in presence of drug under normoxia and hypoxia are shown as (\*) if  $P < 0.05$  and (\*\*) if  $P < 0.001$ .

### DISCUSSION

Hypoxia is an important host factor which favours the virulence of *C. albicans* by different means. Hypoxia is reported to induce distinct transcriptional response in *C. parapsilopsis*, *C. albicans*, and *S. cerevisiae*<sup>19,20,26</sup>. It upregulates the expression of the genes of sterol and glycolytic pathways for implementing the hypoxic

adaptations<sup>19</sup>. Our results indicated that *C. albicans* has required adaptations to grow well under hypoxic conditions (Figure 1). It is reported earlier that adherence is higher in RPMI than in YNB under normoxia at pH 5.6 and pH 7.0<sup>27</sup>.

We found that hypoxia did not enhance adhesion in both the media (Figure 2A), probably due to the effect of hypoxia on cell metabolism<sup>28</sup> and requirement of more time for transcriptional responses. Upregulation of *C. albicans* adhesins, Als1, Als3 and Eap1 is required for adhesion, a step prior to the biofilm development<sup>29,30</sup>.

Yeater (2007) demonstrated that Als1 expression increases at least after 6 hours of incubation but we performed adhesion experiment for 90 minutes only. It is also noteworthy that under hypoxia, two transcription factors, Efg1 and Ace2 repress the filamentous growth in *C. albicans*<sup>14</sup>.

Our results of increased biofilm under hypoxia can be explained by the homology of *C. albicans* Rfg1 with *Saccharomyces cerevisiae* Rox1, a key regulator of hypoxic genes in baker's yeast. Hypoxic regulator function of Rfg1 of *C. albicans* is lost for the virulence regulator function due to evolutionary pressure for surviving as human pathogen.

Under normal conditions, *C. albicans* Rfg1 is a transcription repressor of several genes related to virulence, particularly *HWP1*, *RBT1* and *ALS*<sup>32</sup> but under hypoxia, these virulence determinants are derepressed, increasing the biofilm formation. It has also been shown earlier that biofilm activity is media dependent and higher in RPMI than in YNB media<sup>27</sup>. RPMI has composition similar to human fluids<sup>33</sup> therefore experiments done in RPMI media might have direct clinical significance.

Since hypoxia increased biofilm, we further investigated the effect of hypoxia on biofilm development in the presence of amphotericin B or drug susceptibility of biofilm. Hypoxia did not affect susceptibility remarkably in YNB media because of being less nutrient rich. But hypoxia reduced susceptibility of biofilm to amphotericin B in RPMI (Figure 3B), probably due to the hypoxia dependent modulation of different transcription factors (like *RFG1*, *UPC2*, *EFG1* and *TYE7*) and virulence determinants (like *HWP1*, *RBT1*, *ALS1*, *ALS3* and *EAP1*) which result in increased yeast to hyphal transition, adhesion and biofilm formation. Earlier studies have proven that biofilm form of *C. albicans* is more resistant to antifungals<sup>34,35</sup>.

Amphotericin B is a polyene which target ergosterol of the fungal cell membrane to generate pores<sup>36,37</sup> and hypoxia reduces ergosterol level in yeast by affecting different steps of ergosterol biosynthesis involving oxygen dependent enzymes<sup>28</sup>. It has been demonstrated in previous studies that polyene resistance in *Candida* species results when ergosterol content lowers<sup>38,39</sup>. Therefore, in the present study, increased resistance of



biofilm to the antifungal drug might be the manifestations of increased biofilm and reduced ergosterol level under hypoxic condition.

To our knowledge, this is the first direct study on *in vitro* virulence properties of *C. albicans* under hypoxia in RPMI and YNB media. Further studies are being undertaken to find out the molecular targets, effective under hypoxic conditions to develop effective anti-*Candida* drugs.

## CONCLUSION

Findings of present study clearly indicate that *C. albicans* has adaptations for hypoxic mode of life style, as present inside host tissues. Hypoxia enhanced the biofilm formation in the growth media similar to body fluid i.e. RPMI. Hypoxia also reduced the susceptibility of biofilm against antifungal drug. Hence, hypoxic adaptations in *C. albicans* support its pathogenic mode of survival inside the host.

**Acknowledgement:** We are extremely thankful Dr. Shashi Bala Singh Director, Defense Institute of Physiology and Allied Sciences, Delhi for giving us permission to perform experiments related to hypoxia chamber in DIPAS. We are grateful to Dr. Amitabha Chakrabarti, DIPAS for allowing us to use his laboratory for hypoxic exposures. PG is supported by the INSPIRE fellowship from Department of Science and Technology, Govt. of India. We are also thankful to Dr. Ashish Thapliyal from Graphic Era University and Mr. Surendra Nath from DIPAS for their supports during course of this study.

## Disclosure Statement

No potential conflict of interest was reported by the authors. This work was supported financially by Graphic Era University, Dehradun.

## REFERENCES

1. Askew C, Sellam A, Epp E, Hogues H, Mullick A, Nantel A, Whiteway M, Transcriptional regulation of carbohydrate metabolism in the human pathogen *Candida albicans*, *Plos Pathogens*, 5, 2009, 1-20.
2. Brunke S, Hube B, Two unlike cousins: *Candida albicans* and *C. glabrata* infection strategies, *Cellular Microbiology*, 15, 2013, 701-708.
3. Pfaller MA, Diekema DJ, Epidemiology of invasive candidiasis: a persistent public health problem, *Clinical Microbiology Reviews*, 20, 2007, 133-163.
4. Antibiotic resistance threats in the United States. (2013). U. S. Department of Health and Human Services, Centers for Disease control and Prevention. (<http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf>).
5. Gow NA, Brown AJ, Odds FC, Fungal morphogenesis and host invasion, *Current Opinion in Microbiology*, 5, 2002, 366-371.
6. Kabir MA, Hussain MA, Ahmad Z, *Candida albicans*: A model organism for studying fungal pathogens, *ISRN Microbiology*, 2012, 2012, 1-15.
7. Ramage G, Walle KV, Wickes BL, Lopez-Ribot JL, Standardized method for *in vitro* antifungal susceptibility testing of *Candida albicans* biofilm. *Antimicrobial Agents and Chemotherapy*, 45, 2001, 2475-2479.
8. Ramage G, Martinez JP, Lopez-Ribot JL, *Candida* biofilms on implanted biomaterials: a clinically significant problem, *FEMS Yeast Research*, 6, 2006, 979-986.
9. Kessler M, Höper J, Schäfer D & Starlinger H, Sauerst off transport im Gewebe, In *Mikrozirkulation*. Ahnefeld FW, Burri C, Dick W and Halmágyi M. (eds). Berlin, Heidelberg, New York: Springer Verlag, 1974, 36–52.
10. Lewis JS, Lee JA, Underwood JCE, Harris AL, Lewis CE, Macrophage responses to hypoxia: relevance to disease mechanisms, *Journal of Leukocyte Biology*, 66, 1999, 889-900.
11. Biswas SK, Chaffin WL, Anaerobic growth of *Candida albicans* does not support biofilm formation under similar conditions used for aerobic biofilm, *Current Microbiology*, 51, 2005, 100-104.
12. Thein ZM, Samaranyake YH, Samaranyake LP, *In vitro* biofilm formation of *Candida albicans* and non-*albicans Candida* species under dynamic and anaerobic conditions, *Achieves of Oral Biology*, 52, 2007, 761-768.
13. Ernst JF, Tielker D, Responses to hypoxia in fungal pathogens, *Cellular Microbiology*, 11, 2009, 183-190.
14. Grahl N, Shepardson KM, Chung D, Cramer RA, Hypoxia and Fungal pathogenesis: to air or not to air? *Eukaryot Cell*, 11, 2012, 560-571.
15. Butler G, Hypoxia and gene expression in eukaryotic microbes, *Annual Review of Microbiology*, 67, 2013, 291-312.
16. He M, Du M, Fan M, Bian Z, *In vitro* activity of eugenol against *Candida albicans* biofilms, *Mycopathologia*, 163, 2007, 137-143.
17. Vik A, Rine J, Upc2p and Ecm22p, dual regulators of sterol biosynthesis in *Saccharomyces cerevisiae*, *Molecular and Cellular Biology*, 21, 2001, 6395-6405.
18. Setadi ER, Doedi T, Cottier F, Noffz C, Ernst JF, Transcriptional response of *Candida albicans* to hypoxia: linkage of oxygen sensing and Efg1p-regulatory networks, *Journal of Molecular Biology*, 361, 2006, 399-411.
19. Synnott JM, Guida A, Mulhern-Haughey S, Higgins DG, Butler G, Regulation of the hypoxic response in *Candida albicans*, *Eukaryotic Cell*, 9, 2010, 1734-1746.
20. Rossignol T, Ding C, Guida A, d'Enfert C, Higgins DG, Butler G, Correlation between biofilm formation and the hypoxic response in *Candida parapsilosis*, *Eukaryotic Cell*, 8, 2009, 550-559.
21. Gupta P, Nath S, Meena RC, Kumar N, Comparative effects of hypoxia and hypoxia mimetic cobalt chloride on *in vitro* adhesion, biofilm formation and susceptibility to amphotericin B of *Candida glabrata*, *Journal de Mycologie Médicale*, 24, 2014, e169-177.
22. Lee H, Bien CM, Hughes AL, Espenshade PJ, Kwon-Chung KJ, Chang YC, Cobalt chloride, a hypoxia-mimicking agent,



- targets sterol synthesis in the pathogenic fungus *Cryptococcus neoforma*. *Molecular Microbiology*, 65, 2007, 1018-1033.
23. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA, Global Antifungal Surveillance Group, Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of *Candida* species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion, *Journal of Clinical Microbiology*, 48, 2010, 1366–1377.
  24. Kumar N, Meena RC, Chakrabarti A, Over-expression of *YLR162W* in *Saccharomyces cerevisiae* inhibits cell proliferation and renders cell susceptible to the hypoxic conditions induced by  $\text{CoCl}_2$ , *Indian Journal of Microbiology*, 51, 2011, 206–211.
  25. Riera M, Mogensen E, Enfert C, Janbon G, New regulators of biofilm development in *Candida glabrata*., *Research in Microbiology*, 163, 2012, 297-307.
  26. Vasconcelles MJ, Kevin YJ, Identification and characterization of a low oxygen response element involved in the hypoxic induction of a family of *Saccharomyces cerevisiae* genes, *Journal of Biological Chemistry*, 276, 2001, 14374–14384.
  27. Kucharikova S, Tournu H, Lagrou K, Dijck PV, Bujdakova H, Detailed comparison of *Candida albicans* and *Candida glabrata* biofilms under different conditions and their susceptibility to caspofungin and anidulafungin, *Journal of Medical Microbiology*, 60, 2011, 1261-1269.
  28. Gleason JE, Corrigan DJ, Cox JE, Reddi AR, McGinnis LA, Culotta VC, Analysis of hypoxia and hypoxia-like states through metabolite profiling, *PLoS One*, 6, 2011, 1-15.
  29. Li F, Svarovsky MJ, Karlsson AJ, Wagner JP, Merchillo K, Oshel P, Andes D, Palecek SP, Eap1p, an adhesin that mediates *Candida albicans* biofilm formation *in vitro* and *in vivo*, *Eukaryotic Cell*, 6, 2007, 931-939.
  30. Nailis H, Kucharikova S, Ricicova M, Dijck PV, Deforce D, Nelis H, Coenye T, Real-time PCR expression profiling of genes encoding potential virulence factors in *Candida albicans* biofilms: identification of model-dependent and independent gene expression, *BMC Microbiology*, 10, 2010, 114.
  31. Yeater KM, Chandra J, Cheng G, Mukherjee PK, Zhao X, Rodriguez-Zas SL, Kwast KE, Ghannoum MA, Hoyer LL, Temporal analysis of *Candida albicans* gene expression during biofilm development, *Microbiology*, 153, 2007, 2373-2385.
  32. Kadosh D, Johnson AD, Rfg1, a protein related to *Saccharomyces cerevisiae* hypoxic regulator Rox1, controls filamentous growth and virulence in *Candida albicans*, *Molecular and Cellular Biology*, 21, 2001, 2496-2505.
  33. Chandra J, Patel JD, Li J, Zhou G, Mukherjee PK, McCormick TS, Anderson JM, Ghannoum MA, Modification of surface properties of biomaterials influences the ability of *Candida albicans* to form biofilms, *Applied and Environmental Microbiology*, 71, 2005, 8795-8801.
  34. Donlan RM, Costerton JW, Biofilms: survival mechanisms of clinically relevant microorganisms, *Clinical Microbiology Review*, 15, 2002, 608-611.
  35. Douglas LJ, *Candida* biofilms and their role in infection, *Trends in Microbiology Review*, 11, 2003, 30-36.
  36. Ghannoum MA, Rice LB, Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance, *Clinical Microbiology Reviews*, 12, 1999, 501-517.
  37. Silva S, Negri M, Henriques M, Oliveria R, Williams DW, Azeredo J, *Candida glabrata*, *Candida parapsilosis* and *Candida tropicalis*: biology, epidemiology, pathogenicity and antifungal resistance, *FEMS Microbiology Review*, 36, 2012, 288-305.
  38. Dick JD, Merz WG, Saral R, Incidence of polyene-resistant yeasts recovered from clinical specimens, *Antimicrobial Agents and Chemotherapy*, 18, 1980, 158–163.
  39. Lupeti A, Danesi R, Campa M, Tacca MD, Kelly S, Molecular basis of resistance to azole antifungals, *Trends in Molecular Medicine*, 8, 2002, 76-81.

**Conflict of Interest:** None.

